Insuman Comb 15 Solostar (Insulin Human)

Insulin human mimics the action of endogenous pancreatic insulin. After subcutaneous injection it binds to insulin receptors on muscle, fat and liver cells, activating intracellular tyrosine kinase pathways. This promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, while simultaneously suppressing hepatic glucose production, glycogenolysis, and lipolysis, thereby lowering circulating blood glucose levels.

The dose of Insuman Comb 15 Solostar is individualized by the prescribing healthcare professional. Dosing is based on factors such as the patient’s current blood glucose readings, carbohydrate intake, body weight, renal and hepatic function, and overall treatment goals. Patients should follow the specific instructions provided by their clinician and adjust the pen’s dose according to regular glucose monitoring.

Insulin human is classified as pregnancy category B, indicating no evidence of risk in animal studies and a lack of well‑controlled human data. It is generally considered safe for use in pregnant women when required to control maternal hyperglycaemia, as uncontrolled diabetes poses greater risk to the fetus. Breastfeeding mothers should also use insulin under medical guidance, as only minimal amounts are transferred into breast milk.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the desired quantity of Insuman Comb 15 Solostar. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with any required import documentation.

Insuman Comb 15 Solostar contains human insulin, whereas many other rapid‑acting products use insulin analogues such as insulin lispro, aspart or glulisine. Human insulin has a slightly longer onset and duration compared with analogues, which may affect timing of meals and dosing flexibility. However, it provides comparable glucose‑lowering efficacy and is often chosen for its established safety profile and cost considerations in certain markets.

The pen should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F) and protected from direct light. Do not freeze or shake the device. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, but any remaining insulin should be discarded after this period. Always keep the pen in its original packaging.

Insuman Comb 15 Solostar is administered subcutaneously using the pre‑filled pen. The injection site should be rotated among the abdomen, thigh, or upper arm to reduce lipodystrophy risk. The pen is primed according to the manufacturer’s instructions before the first use, and the dose is selected by turning the dose selector to the prescribed units. After injection, the needle is safely disposed of in an approved sharps container.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness, seizures, or accidents if not promptly treated; allergic reactions ranging from urticaria to anaphylaxis; and lipodystrophy that may impair insulin absorption. Patients should be educated to recognize early signs of hypoglycemia, monitor blood glucose regularly, and seek immediate medical attention for any signs of a severe allergic response.

Insuman Comb 15 Solostar should not be used by individuals with a known hypersensitivity to human insulin or any of the pen’s excipients. It is also contraindicated in patients experiencing hypoglycemia unawareness where they cannot recognize low‑blood‑glucose symptoms, and in those with severe renal or hepatic failure unless dose adjustments are made under close medical supervision. Consultation with a healthcare provider is essential before initiating therapy.